KNSA vs. NUVL, GRFS, TGTX, AXSM, VKTX, KRYS, OGN, SRRK, ALVO, and RARE
Should you be buying Kiniksa Pharmaceuticals stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals include Nuvalent (NUVL), Grifols (GRFS), TG Therapeutics (TGTX), Axsome Therapeutics (AXSM), Viking Therapeutics (VKTX), Krystal Biotech (KRYS), Organon & Co. (OGN), Scholar Rock (SRRK), Alvotech (ALVO), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry.
Kiniksa Pharmaceuticals vs.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, community ranking, profitability, media sentiment, analyst recommendations, risk and institutional ownership.
Kiniksa Pharmaceuticals has higher revenue and earnings than Nuvalent. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.
In the previous week, Kiniksa Pharmaceuticals had 4 more articles in the media than Nuvalent. MarketBeat recorded 20 mentions for Kiniksa Pharmaceuticals and 16 mentions for Nuvalent. Kiniksa Pharmaceuticals' average media sentiment score of 0.50 beat Nuvalent's score of 0.42 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the media.
Kiniksa Pharmaceuticals received 128 more outperform votes than Nuvalent when rated by MarketBeat users. However, 78.18% of users gave Nuvalent an outperform vote while only 65.02% of users gave Kiniksa Pharmaceuticals an outperform vote.
Nuvalent has a net margin of 0.00% compared to Kiniksa Pharmaceuticals' net margin of -2.36%. Kiniksa Pharmaceuticals' return on equity of -7.31% beat Nuvalent's return on equity.
54.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 54.6% of Kiniksa Pharmaceuticals shares are held by company insiders. Comparatively, 12.5% of Nuvalent shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Kiniksa Pharmaceuticals currently has a consensus price target of $36.60, indicating a potential upside of 97.41%. Nuvalent has a consensus price target of $112.36, indicating a potential upside of 48.16%. Given Kiniksa Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Kiniksa Pharmaceuticals is more favorable than Nuvalent.
Kiniksa Pharmaceuticals has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.
Summary
Kiniksa Pharmaceuticals beats Nuvalent on 11 of the 18 factors compared between the two stocks.
Get Kiniksa Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kiniksa Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:KNSA) was last updated on 1/20/2025 by MarketBeat.com Staff
Free KNSA Stock Alerts